Systemic strategies for prostate cancer

Minerva Urologica e Nefrologica

Volumn 59, Issue 1, 2007, Pages 11-25

  Armstrong, A J ^a,b,c   Febbo, P G ^a,b,c   George, D J ^a,b,c   Moul, J ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

Adjuvant, pharmaceutic; Chemotherapy; Immunotherapy; Neoadjuvant therapy; Neovascularization, physiologic; Prostatic neoplasms, therapy; Vitamin D

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AP 23573; ATRASENTAN; BEVACIZUMAB; CELECOXIB; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; EVEROLIMUS; GEFITINIB; GONADORELIN AGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; KETOCONAZOLE; LAPATINIB; LEUPRORELIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; PREDNISONE; PROVENGE; RAPAMYCIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB; VORINOSTAT; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTHRALGIA; CANCER THERAPY; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; MALAISE; MEDICAL DECISION MAKING; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RIGOR; SOLID TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 34250892441     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
3. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18: 3352-9.
4. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
5. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, TomaszewskiJE, Schultz D et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166:2185-8.
6. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292: 821-7.
7. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
8. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42.
9. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40.
10. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol 2005;23:8186-91.
11. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006;12:152-8.
12. Heath EI, DeWeese TL, Partin AW, De Marzo AM, Groopman JD, Nelson WG et al. The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. Clin Prostate Cancer 2002;1:182-7.
13. Lerut E, Roskams T, Goossens E, Bootle D, Dimitrijevic S, Stumm M et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). J Clin Oncol 2005;23(16 Suppl):3071.
14. Demark W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001;58:47-52.
15. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
17. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
18. Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. Rev Urol 2003;5 Suppl 2:S42-7.
19. Rosenbaum E, Kibel A, Roth BJ, Wilding G, Dreicer R, Chatta G et al. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): preliminary data of a multicenter pilot trial. J Clin Oncol 2004;22(14 Suppl):4649.
20. Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Semin Oncol 2001;28(4 Suppl 15):22-31.
21. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11:4905-11.
22. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9.
23. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-46.
24. Bolla M, Van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366: 572-8.
25. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
26. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004;22: 4109-18.
27. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
28. Sweeney CJ. ECOG: CHAARTED - ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol 2006;4:588-90.
29. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918-25.
30. Armstrong AJ, Garrett-Mayer ES, Ou Yang Y, Carducci M, Tannock I, De wit R et al. Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC). Am Soc Clin Oncol Prostate Cancer Symp 2-21-2007.
31. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr. et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21.
32. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-300.
33. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17: 3461-7.
34. Armstrong AJ, Garrett-Mayer ES, Ou Yang Y, De Wit R, Tannock I, Eisenberger M. Limitations of the current progression-free survival (PFS) definition in hormone-refractory prostate cancer (HRPC): benefit associated with continuation of docetaxel beyond TAX327 protocol-defined progression. Am Soc Clin Oncol Prostate Cancer Symp 2-21-2007.
35. Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock IF. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol 2006;24(18 Suppl):4516.
36. Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer. Clin Adv Hematol Oncol 2005;3:271-82.
37. Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep 2005;7:220-7.
38. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
39. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4.
40. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
41. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6.
42. Picus J, Halabi S, Rini BI. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CAL-GB 90006. Proc Am Soc Clin Oncol 2003;22:A1578.
43. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-9.
44. Dahut WL, Scripture CD, Posadas EM, Wu S, Arlen PM, Gulley JL et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol 2006;24(18 Suppl):4506.
45. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74.
46. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6.
47. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
48. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006;24(18 Suppl):LBA4.
49. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxombicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
50. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005;11:1704-12.
51. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455-60.
52. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004;60:332-7.
53. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65:3404-9.
54. Mendiratta P, Armstrong AJ, George DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol 2007;9 Suppl 1:S9-S19.
55. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
56. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX(R) vaccine for prostate cancer. Urol Oncol 2006;24:419-24.
57. Simons JW, Higano C, Smith D, Corman J, Steidle C, Gittelman M et al. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC). J Clin Oncol 2005;23(16 Suppl):2517.
58. Small E, Higano C, Smith D, Corman J, Centeno A, Steidle C et al. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 2004;22(14 Suppl):4565.
59. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005;23:8262-9.
60. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006;24:442-7.
61. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16:83-95.
62. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-9.
63. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:203-10.
64. Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006;26(4A):2525-30.
65. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-Dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10.
66. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:669-74.
67. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
68. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
69. Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003;170(6 Pt 2):S65-7.
70. Carducci M, Nelson JB, Saad F, Schulman CC, Dearnaley DP, Sleep DJ et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. J Clin Oncol 2004;22(14 Suppl):4508.
71. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
72. Vogelzang NJ, Nelson JB, Schulman CC, Dearnaley DP, Saad F, Sleep DJ et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(16 Suppl):4563.
73. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8:725-32.
74. Loprinzi CL. Denosumab in postmenopausal women with low bone mineral density. Curr Oncol Rep 2006;8:267-8.
75. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8.
76. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23:8247-52.
77. Lin AM, Rosenberg JE, Weinberg VK, Kelly WK, Michaelson MD, Hussain M et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol 2006;24(18 Suppl):4558.
78. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17.
79. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003;89:968-70.
80. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 2005;4:86-90.
81. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005;96:990-4.
82. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9.
83. Petrylak D, Sartor O, Witje F, Berry WR, Koletsky A, Falcon S et al. A phase III, randomized, double-blind trial of satraplatin and prednisone is placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Sympsium 2-21-2007.